BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 28347667)

  • 1. Discovery of novel BRD4 inhibitors by high-throughput screening, crystallography, and cell-based assays.
    Sun Z; Zhang H; Chen Z; Xie Y; Jiang H; Chen L; Ding H; Zhang Y; Jiang H; Zheng M; Luo C
    Bioorg Med Chem Lett; 2017 May; 27(9):2003-2009. PubMed ID: 28347667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and biological evaluation of benzo[cd]indol-2(1H)-ones derivatives as BRD4 inhibitors.
    Feng Y; Xiao S; Chen Y; Jiang H; Liu N; Luo C; Chen S; Chen H
    Eur J Med Chem; 2018 May; 152():264-273. PubMed ID: 29730189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of a Small-Molecule Bromodomain-Containing Protein 4 (BRD4) Inhibitor That Induces AMP-Activated Protein Kinase-Modulated Autophagy-Associated Cell Death in Breast Cancer.
    Ouyang L; Zhang L; Liu J; Fu L; Yao D; Zhao Y; Zhang S; Wang G; He G; Liu B
    J Med Chem; 2017 Dec; 60(24):9990-10012. PubMed ID: 29172540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell-based protein stabilization assays for the detection of interactions between small-molecule inhibitors and BRD4.
    Schulze J; Moosmayer D; Weiske J; Fernández-Montalván A; Herbst C; Jung M; Haendler B; Bader B
    J Biomol Screen; 2015 Feb; 20(2):180-9. PubMed ID: 25266565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In silico study directed towards identification of novel high-affinity inhibitors targeting an oncogenic protein: BRD4-BD1.
    Tumdam R; Kumar A; Subbarao N; Balaji BS
    SAR QSAR Environ Res; 2018 Dec; 29(12):975-996. PubMed ID: 30411639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and characterization of bromodomain 2-specific inhibitors of BRDT.
    Yu Z; Ku AF; Anglin JL; Sharma R; Ucisik MN; Faver JC; Li F; Nyshadham P; Simmons N; Sharma KL; Nagarajan S; Riehle K; Kaur G; Sankaran B; Storl-Desmond M; Palmer SS; Young DW; Kim C; Matzuk MM
    Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33637650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacophore-based virtual screening, molecular docking, molecular dynamics simulation, and biological evaluation for the discovery of novel BRD4 inhibitors.
    Yan G; Hou M; Luo J; Pu C; Hou X; Lan S; Li R
    Chem Biol Drug Des; 2018 Feb; 91(2):478-490. PubMed ID: 28901664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation.
    Xue X; Zhang Y; Liu Z; Song M; Xing Y; Xiang Q; Wang Z; Tu Z; Zhou Y; Ding K; Xu Y
    J Med Chem; 2016 Feb; 59(4):1565-79. PubMed ID: 26731490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization.
    Zhao L; Wang Y; Cao D; Chen T; Wang Q; Li Y; Xu Y; Zhang N; Wang X; Chen D; Chen L; Chen YL; Xia G; Shi Z; Liu YC; Lin Y; Miao Z; Shen J; Xiong B
    J Med Chem; 2015 Feb; 58(3):1281-97. PubMed ID: 25559428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of small-molecule BRD4 degraders based on pyrrolopyridone derivative.
    Zhang J; Chen P; Zhu P; Zheng P; Wang T; Wang L; Xu C; Zhou J; Zhang H
    Bioorg Chem; 2020 Jun; 99():103817. PubMed ID: 32361153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High resolution crystal structure of BRD4-BD1 in complex with a novel inhibitor precursor.
    Ma X; Wang M; Wang F; Li J; Zhang Z; Zhu J; Liu B
    Biochem Biophys Res Commun; 2024 Jan; 690():149284. PubMed ID: 38006801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and characterization of bivalent BET inhibitors.
    Tanaka M; Roberts JM; Seo HS; Souza A; Paulk J; Scott TG; DeAngelo SL; Dhe-Paganon S; Bradner JE
    Nat Chem Biol; 2016 Dec; 12(12):1089-1096. PubMed ID: 27775715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of BRD4 bromodomain inhibitors by fragment-based high-throughput docking.
    Zhao H; Gartenmann L; Dong J; Spiliotopoulos D; Caflisch A
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2493-6. PubMed ID: 24767840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
    Hu J; Wang Y; Li Y; Xu L; Cao D; Song S; Damaneh MS; Wang X; Meng T; Chen YL; Shen J; Miao Z; Xiong B
    Eur J Med Chem; 2017 Sep; 137():176-195. PubMed ID: 28586718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent and selective bivalent inhibitors of BET bromodomains.
    Waring MJ; Chen H; Rabow AA; Walker G; Bobby R; Boiko S; Bradbury RH; Callis R; Clark E; Dale I; Daniels DL; Dulak A; Flavell L; Holdgate G; Jowitt TA; Kikhney A; McAlister M; Méndez J; Ogg D; Patel J; Petteruti P; Robb GR; Robers MB; Saif S; Stratton N; Svergun DI; Wang W; Whittaker D; Wilson DM; Yao Y
    Nat Chem Biol; 2016 Dec; 12(12):1097-1104. PubMed ID: 27775716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
    Ran X; Zhao Y; Liu L; Bai L; Yang CY; Zhou B; Meagher JL; Chinnaswamy K; Stuckey JA; Wang S
    J Med Chem; 2015 Jun; 58(12):4927-39. PubMed ID: 26080064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of the natural product 3',4',7,8-tetrahydroxyflavone as a novel and potent selective BRD4 bromodomain 2 inhibitor.
    Li J; Zou W; Yu K; Liu B; Liang W; Wang L; Lu Y; Jiang Z; Wang A; Zhu J
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):903-913. PubMed ID: 33820450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of novel small molecule induced selective degradation of the bromodomain and extra-terminal (BET) bromodomain protein BRD4 and BRD2 with cellular potencies.
    Jiang F; Wei Q; Li H; Li H; Cui Y; Ma Y; Chen H; Cao P; Lu T; Chen Y
    Bioorg Med Chem; 2020 Jan; 28(1):115181. PubMed ID: 31767403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NMR-based platform for fragment-based lead discovery used in screening BRD4-targeted compounds.
    Yu JL; Chen TT; Zhou C; Lian FL; Tang XL; Wen Y; Shen JK; Xu YC; Xiong B; Zhang NX
    Acta Pharmacol Sin; 2016 Jul; 37(7):984-93. PubMed ID: 27238211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein targeting chimeric molecules specific for dual bromodomain 4 (BRD4) and Polo-like kinase 1 (PLK1) proteins in acute myeloid leukemia cells.
    Mu X; Bai L; Xu Y; Wang J; Lu H
    Biochem Biophys Res Commun; 2020 Jan; 521(4):833-839. PubMed ID: 31708096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.